In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …

Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of
HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART …

Combination antiretroviral therapy (ART) can block multiple stages of the HIV-1 life cycle to
prevent progression to AIDS in people living with HIV-1. However, owing to the persistence …

Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …

Development of improved approaches for HIV-1 prevention will likely be required for a
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early …

HIV-1 sequence diversity presents a major challenge for the clinical development of broadly
neutralizing antibodies (bNAbs) for both therapy and prevention. Sequence variation in …

Antigenic mimicry is a fundamental tenet of structure-based vaccinology. Vaccine strategies
for the human immunodeficiency virus type 1 (HIV-1) focus on the mimicry of its envelope …

Broadly neutralizing antibodies (bNAbs) protect against HIV infection in non-human
primates and their efficacy may be enhanced through interaction with Fc receptors on …